Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience
Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giovanni Martinelli(University of Bologna), Simona Soverini(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Maria Chiara Abbenante(University of Bologna), Francesca Volpato(University of Bologna), Giovanni Marconi(University of Bologna), Silvia Lo Monaco(University of Bologna), Carolina Terragna(Fondazione Gimema Onlus), Caterina De Benedittis(University of Bologna), Sarah Parisi(University of Bologna), Alessandra Santoro(Ospedale Vincenzo Cervello), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Elena Tenti(University of Bologna), Antonella Padella(University of Bologna), Carmen Baldazzi(University of Bologna), Enrica Imbrogno(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Federica Frabetti(University of Bologna), Valentina Robustelli(University of Bologna)
Cited by 2
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486